Theoretically, by designing small molecule drugs, antibody–drug conjugates, peptide-based drugs, or other nanomedicine techniques that specifically bind to and interfere with the interaction between FMRP and m6A-modified sites, the abnormal stabilization of EGFR mRNA can be inhibited, thereby slowing tumor growth and metastasis.53 Here, EGFR is linked to neoplasm.